Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by EyeDontBelieveUon Mar 15, 2017 3:01pm
131 Views
Post# 25983822

RE:RE:Guidance.....

RE:RE:Guidance.....Correct - without guidlance funds can not buy this stock (regulations prohibit purchase), and institutions won't touch it.  The share price will not be able to go upwards with retail purchases alone.  This is unfortunate for any retail long on this stock.


GenericAdvocate wrote: If they can't offer guidance, then institutions will not ...   and many CAN NOT..   buy ....

That is like saying in December, well we can't offer guidance because we don't know if Brexit is going through...   

The end result is, that the investment community has NO confidence that they can service their debt without guidance.

So the share price will continue to slide.  Insiders are probably short their own stock


happyretirement wrote: How could anyone expect Concordia which has a majority of their drugs sold in the UK which should finalize the Health Service Medical Supplies (Costs) Bill in the coming months and has already had many of their drugs changed from both "A & C" to "M" which puts pricing control into the hands of the DoH, no company in their right minds would make any type of estimate with the current outlook for 2017 from the UK Government.....CMA issues will be something that could be pushed out till next year and beyond as shown from previous cases such as Pfizer and others....

JMO




<< Previous
Bullboard Posts
Next >>